SITE SPECIFIC DATA ITEMS (SSDI)/ GRADE

Description

LDH (Lactate Dehydrogenase) is an enzyme involved in conversion of sugars to energy and present in most cells in the body. Elevated LDH is an adverse prognostic factor for plasma cell myeloma and melanoma of the skin. The Revised International Staging System (RISS or R-ISS) is now used to stage plasma cell myeloma (9732/3), using several different criteria. The stages are based on the absence or presence of the following related criteria. * 3931: Serum Beta-2 Microglobulin Pretreatment Level * 3930: Serum Albumin Pretreatment Level * 3857: High Risk Cytogenetics * 3869: LDH Level Required for Staging: The AJCC Staging System Plasma Cell Myeloma and Plasma Cell Disorders (9732/3 only) and EOD. * Note: RISS stage is not applicable for the descriptions of plasma multiple myeloma that are listed in the codes 1 and 9 in the SSDI Schema Discriminator 1: Plasma Cell Myeloma Terminology. If you have coded 1 or 9 for this Schema Discriminator, the four data items listed above are BLANK. The RISS stages are * Stage I: Serum Beta-2-microglobulin <3.5 mg/L and serum albumin > 3.5 g/dL and no high-risk cytogenetics and Normal LDH * Stage II: Not R-ISS I or III * Stage III: Serum Beta-2-microglobulin > 5.5 mg/L and high-risk cytogenetics and/or high LDH

Notes

**Note 1:** **Physician statement** * Physician statement of LDH Level can be used to code this data item when no other information is available **Note 2:** **Pretreatment results only** * Record this data item based on a **blood test** performed at diagnosis (pre-treatment). Use the highest value available. * Do not use results from a urine test **Note 3:** **Component of RISS Stage** * LDH level is part of the Revised International Staging (RISS). Use the lab’s reference range to determine if LDH is normal or elevated